Foresite Capital, an American venture capital and growth equity firm, Samsara BioCapital, an investment company and venBio Partners, a life sciences investment firm, led a $259m Series C round in Alumis, a clinical-stage biopharmaceutical company. "We are pleased to announce our successful Series C financing and we are grateful for the support of our strong investor syndicate, a group that shares our commitment to transforming the treatment paradigm for patients living with immune-mediated diseases. This investment will support the continued clinical development of ESK-001, building on promising data that have demonstrated full, sustained target inhibition leading to a potentially best-in-class oral TYK2 inhibitor profile,” Martin Babler, Alumis President and CEO.